Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.

JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.

DataM Intelligence | competitive Intelligence Explore the evolving Multiple Myeloma market: drug innovations, emerging therapies, and key p ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Twelve years ago, while coaching in the Southeastern Conference at the University of Kentucky, his life took an unexpected ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Making CAR-T cells, though, is an art, with so many possible variables that it can be hard to hit on one that works. And it ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products ...

The blood cancer multiple myeloma is deadly. This disease is personal for us because one of our best friends and colleagues ...

ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple ...